Introducing Microbio

Microbio is an Australian biotech startup that plans to change the course of pathogen detection. Our novel diagnostic method combines the latest advances in bioinformatics, genomics and molecular microbiology to deliver rapid pathogen detection using qPCR. Developed in collaboration with Australian clinicians, Microbio’s flagship product InfectID-BSI has been designed with clinical decision-making in mind, to… Continue reading Introducing Microbio

ASM Microbe 2024: How molecular diagnostic tests can inform clinical decision-making

Attendees at the American Society for Microbiology (ASM) Microbe 2024 in Atlanta, Georgia are invited to view three posters presented by Microbio Founder and Chief Scientific Officer, Dr Flavia Huygens. If you’re curious about the power of molecular diagnostics to support clinical decision-making in sepsis, a discussion with Dr Huygens is highly recommended! đź’ˇFriday 14… Continue reading ASM Microbe 2024: How molecular diagnostic tests can inform clinical decision-making

Categorised as Blog post

Microbio appoints Colin Keating as CEO

Brisbane, 24 October 2023 – Microbio Ltd, an Australian molecular pathogen diagnostics company, is pleased to announce the appointment of Colin Keating as CEO, effective from 1 November 2023. Mr Keating joined Microbio as interim COO in May and assumed the role of interim CEO in early June. Mr Keating’s experience delivering transformation programs at… Continue reading Microbio appoints Colin Keating as CEO

Microbio featured on Smart Company

Microbio has been featured by Smart Company in an article highlighting the commercialisation of InfectID-BSI and how it has benefitted from our participation in the Brisbane Economic Development Agency’s MedTech Accelerator program. Microbio develops pathogen test to identify and treat sepsis (